Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc. (CYCN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cycn · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cyclerion Therapeutics, Inc.You CYCN | $13M | N/A | — | — |
 Addex Therapeutics Ltd ADXN | $4M | N/A | — | -$7.20 |
 AIM ImmunoTech Inc. AIM | $2M | N/A | — | -$8.62 |
 Pasithea Therapeutics Corp. KTTA | $4M | N/A | — | -$2.91 |
 NovaBay Pharmaceuticals, Inc. NBY | $39M | N/A | — | -$3.80 |
 Polyrizon Ltd. PLRZ | $14M | N/A | — | -$2.07 |
 Quoin Pharmaceuticals, Ltd. QNRX | $3M | N/A | — | -$10.55 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cyclerion Therapeutics, Inc. (CYCN) measures how much investors pay for each dollar of the company's trailing earnings. CYCN's current PE ratio of N/A is calculated by dividing its stock price of $3.01 by its TTM earnings per share of —.
Frequently asked questions
CYCN pe ratio · 6 questionsCYCN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $3.01 and TTM EPS of —. Data sourced from Financial Modeling Prep via CYCN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cyclerion Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09